A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 24, 2022

Primary Completion Date

November 30, 2022

Study Completion Date

May 1, 2023

Conditions

E.Coli InfectionsBloodstream Infection

Interventions

DRUG

SNIPR001

SNIPR001 is a live biotherapeutic product consisting of genetically modified bacteriophages specifically targeting Escherichia coli

DRUG

Placebo

Matching placebo

Trial Locations (1)

Medpace Clinical Pharmacology, Cincinnati

All Listed Sponsors

collaborator

Biomedical Advanced Research and Development Authority

FED

collaborator

Wellcome Trust

OTHER

lead

SNIPR Biome Aps.

INDUSTRY